Selected Quarterly Financial Data (Unaudited) (Tables)

12 Months Ended

Jun. 30, 2020

Quarterly Financial Information Disclosure [Abstract]

Schedule of Selected Quarterly Financial Data

The following is selected quarterly financial data for fiscal 2020 and 2019. The sum of the quarters may not equal year-to-date due to rounding.

(in millions, except per common share amounts)	First Quarter (1)			Second Quarter		Third Quarter			Fourth Quarter (2)
Fiscal 2020
Revenue	$	37,341		$	39,735	$	39,157		$	36,689
Gross margin	1,679			1,714		1,885			1,590
Distribution, selling, general and administrative expenses	1,107			1,163		1,165			1,137
Net earnings/(loss)	(4,921		)	220		351			657
Less: Net earnings attributable to noncontrolling interests	(1		)	—		(1		)	(1		)
Net earnings/(loss) attributable to Cardinal Health, Inc.	(4,922		)	220		350			656
Net earnings/(loss) attributable to Cardinal Health, Inc. per common share:
Basic	$	(16.65	)	$	0.75	$	1.20		$	2.25
Diluted	(16.65		)	0.75		1.19			2.23

(1) Includes a $5.63 billion pre-tax charge for the opioid litigation ($5.14 billion after tax).

(2) Includes a $579 million pre-tax gain ($493 million after tax) in connection with the sale of our remaining equity interest in a partnership that owned naviHealth.

(in millions, except per common share amounts)	First Quarter (1)			Second Quarter			Third Quarter		Fourth Quarter
Fiscal 2019
Revenue	$	35,213		$	37,740		$	35,228	$	37,353
Gross margin	1,667			1,730			1,764		1,674
Distribution, selling, general and administrative expenses	1,155			1,064			1,097		1,168
Net earnings/(loss)	594			281			296		194
Less: Net earnings attributable to noncontrolling interests	(1		)	(1		)	—		—
Net earnings/(loss) attributable to Cardinal Health, Inc.	593			280			296		194
Net earnings/(loss) attributable to Cardinal Health, Inc. per common share:
Basic	$	1.95		$	0.94		$	0.99	$	0.65
Diluted (3)	1.94			0.93			0.99		0.65

(1)

Includes a $508 million gain ($378 million after tax) related to the naviHealth divestiture.